Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock

IMM Insider Trading (Immutep)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Immutep Insider Trading History Chart

This chart shows the insider buying and selling history at Immutep by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immutep Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for IMM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Breaking News Just Announced
This tiny telehealth stock is up over 50% in the past month.
Put it on your watchlist now

Immutep Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/4/2021Pete MeyersInsiderExercise500,000A$0.54A$267,500.00
11/6/2020Grant ChamberlainInsiderIssued1,350,000A$0.29A$391,500.00
10/2/2020Pete MeyersInsiderBuy273,637A$0.24A$64,304.70
3/16/2020Grant ChamberlainInsiderBuy360,623A$0.28A$99,892.57
1/2/2020Marc VoigtInsiderIssued1,666,667A$0.26A$433,333.42
8/6/2019Marc VoigtInsiderIssued1,535,813A$0.02A$32,252.07
1/2/2019Russell HowardInsiderBuy2,500,000A$0.03A$70,000.00
See Full Table
Insider Selling at Immutep?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Immutep and related companies.

SEC Filings (Institutional Ownership Changes) for Immutep (ASX:IMM)

Immutep logo
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Â'eftilagimod alpha' or Â'efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Read More on Immutep

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

2,151,332 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Immutep?

Immutep's top insider investors include:
  1. Grant Chamberlain (Insider)
  2. Marc Voigt (Insider)
  3. Pete Meyers (Insider)
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock